(vianews) - the market ended the session with maat pharma (maat.pa) jumping 10.43% to €7.20 on monday while cac 40 rose 0.56% to €7,413.25.
maat pharma's last close was €6.52, 41.26% below its 52-week high of €11.10.
about maat pharma
maat pharma sa, a clinical stage company, engages in the research and development of microbiome biotherapies for the treatment of solid cancer tumors. its products pipeline includes maat013 that has completed phase 2 clinical trials for the treatment of acute graft versus host diseases, as well as in preclinical trials to treat melanoma; maat033, which is in phase 1b clinical trials for the improvement of survival in patients with acute myeloid leukemia or other liquid tumors receiving allogeneic hematopoietic stem cell transplantation; and maat03x for the treatment of solid tumors. the company was incorporated in 2014 and is headquartered in lyon, france.
earnings per share
as for profitability, maat pharma has a trailing twelve months eps of €-1.4.
return on equity
the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -46.11%.
stock price classification
according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, maat pharma's stock is considered to be overbought (>=80).
yearly top and bottom value
maat pharma's stock is valued at €7.20 at 21:32 est, way under its 52-week high of €11.10 and way above its 52-week low of €4.50.
volatility
maat pharma's last week, last month's, and last quarter's current intraday variation average was a negative 2.41%, a negative 0.43%, and a positive 3.28%.
maat pharma's highest amplitude of average volatility was 2.41% (last week), 2.90% (last month), and 3.28% (last quarter).
more news about maat pharma (maat.pa).